Risk-of-bias tools only help if judgments are inspectable. In CoreSR, GLASS grounds each appraisal in quoted study text — the human still decides. No black-box score. #SystematicReview#RiskOfBias#EvidenceSynthesis
“Living” isn’t a methods free pass.
Syst Rev: 23 Cochrane + 23 non-Cochrane LSRs—43% of Cochrane met all 3 need criteria for living mode; 0% of non-Cochrane did. Guideline citations stayed scarce.
#LivingReview#SystematicReview#EvidenceSynthesis
coreSR now runs inside Claude and ChatGPT
I connected the coreSR MCP server and gave Claude one sentence: build a search on sildenafil for pulmonary arterial hypertension, run it, and screen it with TITAN at the strictest setting, randomized trials only.
Twelve minutes later, Claude had searched PubMed and Europe PMC, run TITAN across 1,022 unique records, and written a report that reads like a methods section. It also checked the screen against landmark trials. Two were missing. Claude traced the gap to the search strategy, ran a corrected supplement, and recovered both.
That division of labour is the point. Validated engines do the science. Claude does the legwork. You make the final calls.
The full demo runs under three minutes. Connect at coresr.ai/mcp.
#SystematicReview#EvidenceSynthesis#MetaAnalysis#ClaudeAI
Rapid-review shortcuts rarely flip pooled effects—but they scramble the evidence map.
JCE re-ran 3 WHO LBP SRs (acupuncture, education, TENS) with fewer DBs + 1-reviewer screening/RoB: ≤15% of MAs would change recommendations; COE shifted 13–52% as single-study analyses dropped.
This just published paper documents the excellent and, compared to alternatives, superior performance of the title and abstract screening tool of our CoreSR package.
pubmed.ncbi.nlm.nih.gov/4276…coresr.ai/
Most NMA tools stop at relative effects.
Certainty for each network estimate is a separate job—indirectness, incoherence, imprecision.
CoreSR runs real R NMA/CNMA and native NMA GRADE in one project, question to published review.
Appraising an NMA isn't the same job as appraising a pairwise SR.
JCE scoped critical-appraisal tools for SRs with network meta-analysis and found real gaps in what they cover.
We need tools that stress-test network assumptions—not only study-level RoB.
RoB without a quote trail is hard to audit later. GLASS surfaces the supporting text for each domain; a human still makes the call. Faster appraisal, same accountability. #RiskOfBias#SystematicReview#EvidenceSynthesis
In 17 trauma-mortality studies (n=243,324), ML beat logistic regression by ΔAUC 0.026—and the 95% prediction interval crossed zero (I²=97.9%). Best-of-tournament ML vs one LR is a biased estimand. Only 4/17 low PROBAST RoB.
#PredictionModels#Metaresearch#PROBAST
Most evidence stacks die at the handoff: screening in one tool, RoB in another, NMA in R, GRADE elsewhere. One workspace keeps the audit trail intact from question to published review.
#EvidenceSynthesis#SystematicReview#GRADE
A JCE scoping review found 90 beginner-facing NMA methods resources (2011–2025)—still no single path from nodes to certainty. First-timers stitch Cochrane, GRADE, and PRISMA-NMA alone. Consolidation would cut the black box.
#NetworkMetaAnalysis#SystematicReview